https://www.gsk.com/en-gb/media/press-releases/juluca-dolutegravirrilpivirine-the-first-single-pill-2-drug-regimen-for-the-maintenance-treatment-of-hiv-granted-marketing-approval-by-japan-ministry-of-health-labour-and-welfare/
Juluca (dolutegravir/rilpivirine), the first single pill, 2-drug regimen, for the maintenance...
The Ministry of Health, Labour and Welfare has approved Juluca Combination Tablets for the maintenance treatment of (HIV-1) infection.
the first singledolutegravir rilpivirine
https://www.medlineplus.gov/druginfo/meds/a624038.html
Dolutegravir and Rilpivirine: MedlinePlus Drug Information
Dolutegravir and Rilpivirine: learn about side effects, dosage, special precautions, and more on MedlinePlus
dolutegravirrilpivirinemedlineplusdruginformation
https://www.newswire.ca/news-releases/janssen-announces-two-drug-combination-of-dolutegravir-and-rilpivirine-demonstrates-efficacy-in-maintaining-viral-suppression-in-phase-iii-clinical-studies-613654083.html
Janssen Announces Two-Drug Combination of Dolutegravir and Rilpivirine Demonstrates Efficacy in...
/CNW/ - Janssen Sciences Ireland UC (Janssen) announced positive results from the full data read out for two Phase III studies evaluating the safety and...
drug combination
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolutegravirrilpivirine-at-aids-2018/
ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018 |...
Juluca, the first 2-drug regimen, once daily, single pill regimen, maintains viral suppression through 100 weeks.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-begins-phase-iii-programme-with-dolutegravirrilpivirine-combination-for-hiv-maintenance-therapy/
ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV...
viiv healthcarephase iii